Printer Friendly

U.S. PATENT OFFICE NOTIFIES ENZO BIOCHEM OF PATENT ALLOWANCE FOR GENETIC ANTISENSE TECHNOLOGY

 U.S. PATENT OFFICE NOTIFIES ENZO BIOCHEM OF PATENT ALLOWANCE
 FOR GENETIC ANTISENSE TECHNOLOGY
 FARMINGDALE, N.Y., Aug. 18 /PRNewswire/ -- Enzo Biochem, Inc. (AMEX: ENZ), today announced that it has received from the U.S. Patent and Trademark Office a notification of allowance for a patent filed in 1983 covering genetic antisense technology.
 The allowed patent embraces a technology that makes it possible to regulate the function of any gene in any cell. Enzo Therapeutics, Inc., a wholly owned subsidiary, has exclusively licensed this technology from the Research Foundation of State University of New York (SUNY).
 "We believe this is a highly significant development, since the allowed claims in the forthcoming patent broadly cover the use of genetic antisense, a technology applicable to agriculture, therapeutics and bioprocessing," stated Elazar Rabbani, president of Enzo Biochem. "We are in discussions with a number of companies interested in utilizing the technology for a variety of applications."
 Enzo Biochem and SUNY have also received allowance from the European Patent Office for a European patent covering the same technology.
 Enzo's licensed antisense technology involves regulating a cell with a gene specifically constructed to control the function of another gene in that cell. The constructed gene can contain an inverted segment of a specific gene target. Since a gene essentially produces a message that makes "sense" to the cell, its inverse has been dubbed "antisense." When introduced into a cell containing its gene target, the constructed antisense gene regulates the function of the targeted gene.
 In agriculture, antisense technology is expected to open a wide variety of possibilities for developing plant varieties with specific improved traits that could benefit the nutritional, flavor and handling characteristics of fruits, vegetables and grains, yielding enhanced products and important economies.
 Use of antisense technology is believed to offer promising gene therapy and more conventional medicinal approaches specific to diseases like cancers, AIDS and other viral diseases that take over normal cell functioning and which have heretofore been difficult to stop without also interfering with cell function.
 Enzo Biochem, Inc., is engaged both in the research, development and manufacture of innovative health care products based on molecular biology and genetic engineering techniques and in providing diagnostic services to the medical community.
 -0- 8/18/92
 /CONTACT: Carol Dempster of Enzo Biochem, 212-924-5409; or Steven Anreder of Anreder and Co., 212-421-4020, for Enzo Biochem/
 (ENZ) CO: Enzo Biochem, Inc. ST: New York IN: MTC SU:


GK-OS -- NY009 -- 0823 08/18/92 09:04 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 18, 1992
Words:412
Previous Article:INDE ANNOUNCES SECOND QUARTER RESULTS AND PROJECTED EARNINGS
Next Article:BERGEN BRUNSWIG INCREASES BID FOR DURR-FILLAUER
Topics:


Related Articles
EUROPEAN PATENT OFFICE GRANTS MOLECULAR BIOSYSTEMS BROAD ANTISENSE PATENT
EUROPEAN PATENT OFFICE GRANTS MOLECULAR BIOSYSTEMS BROAD ANTISENSE PATENT
CALGENE SIGNS ANTISENSE PATENT LICENSE WITH THE FRED HUTCHINSON CANCER RESEARCH CENTER
CALGENE PREVAILS IN ENZO PATENT LITIGATION; CALGENE PLANT ANTISENSE PATENT HELD VALID
CALGENE ASKS COURT TO CLARIFY ANTISENSE LITIGATION RULING
Hybridon Receives Notice of Allowability from U.S. Patent Office for Advanced 'Hybrid' Antisense Chemistry
ENZO BIOCHEM GETS NEW PATENT ALLOWANCES IN U.S/CANADA.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters